Phthisiology

doi: 10.25005/2074-0581-2018-20-2-3-212-217
SHORT-TERM CHEMOTHERAPY REGIMEN OF MULTIDRUG-RESISTANT TUBERCULOSIS IN THE KYRGYZ REPUBLIC

E.V. Zhdanova1, G.K. Turdumambetova2

1Department for the Treatment of Multidrug-Resistant Tuberculosis, National Center for Phthisiology, Bishkek, Kyrgyz Republic
2Department of Phthisiology, I.K. Akhunbaev Kyrgyz State Medical Academy, Bishkek, Kyrgyz Republic

Objective: To study the clinical course of tuberculosis (TB) with multiple drug resistance (MDR) in the treatment of short-term courses recommended by the WHO.

Methods: Design of research – a retrospective study of 42 (100%) patients of both sexes aged 18-62 years who were on stationary and then in outpatient treatment with short-term courses in 2017 and received a short course of chemotherapy for MDR TB (4-6 CmMfxPtoCfzZEH / 5 MfxPtoCfzZE) recommended by WHO.

Results: According to the data on treatment outcomes, 4 (9.6%) of the patient because of the serious undesirable setting have been withdrawn from therapy. Out of 33 (78.6%) people with positive sputum test, smear conversion to negative was detected in 1 month already in half of the patients; of 99.2% of patients at the end of 3 months of chemotherapy, the destruction of pulmonary parenchyma persisted in 66.7% of patients. A favorable outcome of therapy was achieved in 73.8%, an unfavorable outcome occurred in 7.1% of cases. 3 (7.1%) of the patient fell out of sight, and 2 (4.8%) patients still continue treatment.

Conclusions: The question of the efficacy of treatment with a short course of chemotherapy in Kyrgyzstan remains open, more objective answers will be given after a long detailed and voluminous analysis of the research conducted. Quite optimistic preliminary results obtained by us, we can say that a shorter duration of treatment will allow access to a more likely effective treatment, so as to reduce the high moment rates of portability treatment in patients. Although it is necessary to further confirm the effectiveness of these expectations it should not listen to the obstacle to the implementation of WHO recommendations.

Keywords: Drug-resistant tuberculosis, multiple drug resistance, short courses of chemotherapy.

Download file:


References
  1. Kadyrov AS. Epidemiologicheskaya situattsiya po tuberkulyozu v Kyrgyzskoy respublike v 2012-2016 godakh [Tuberculosis epidemic in the Kyrgyz republic in 2012-2016]. Nauka, novye tekhnologii i innovatsii Kyrgyzstana. 2017;8:3-7.
  2. Dheda K, Chang KC, Guglielmetti L, Furin J, Schaaf HS, Chesov D, et al. Clinical management of adults and children with multidrug-resistant and extensively drug-resistant tuberculosis. Clin Microbiol Infect. 2017;23(3):131-40. Available from: http://dx.doi.org/10.1016/j.cmi.2016.10.008.
  3. Zhdanova EV, Turdumambetova GK. Klinicheskie aspekty dignostiki i techeniya rezistentnykh form tuberkulyoza za period 2012-2016 gody v Kyrgyzskoy Respublike [Clinical aspects of diagnostics and the current of resistant forms of tuberculosis for the period 2013-2016 in the Kyrgyz Republic]. Nauka, novye tekhnologii i innovatsii Kyrgyzstana. 2017;8:27-9.
  4. Khanin AL, Dolgikh AC, Viktorova AB. Problemy lekarstvenno-ustoychivogo tuberkulyoza. Vozmozhnye puti resheniya na primere krupnogo promyshlennogo goroda Sibiri [The problem of drug-resistant tuberculosis. Possible solutions to an example of big industrial city of Siberia]. Vestnik sovremennoy klinicheskoy meditsiny. 2011;4(1):9-11.
  5. Skryagina EM, Gurevich AM, Zalutskaya OM. Sovremennye printsipy diagnostiki i lecheniya tuberkulyoza c mnozhestvennoy lekarstvennoy ustoychivost’yu [Modern principals of diagnosis and treatment of multidrugresistant tuberculosis]. Lechebnoe delo. 2014;3:27-32.
  6. Bloss E, Kukša L, Holtz TH, Riekstina V, Skripconoka V, Kammerer S, Leimane V. Pobochnye proyavleniya, svyazannye s lecheniem tuberkulyoza s mnozhestvennoy lekarstvennoy ustoychivost’yu, Latviya, 2000-2004 gg. [Side effects associated with the treatment of multi-drug resistant tuberculosis, Latvia, 2000-2004 y.]. Tuberkulyoz i lyogochnye zabolevaniya. 2010;2(1):126-34.
  7. Caminero J, Sotgiu G, Zumla A, Migliori GB. Best drag treatment for multidrugresistant and extensively drug-resistant tuberculosis. Lancet Infect Dis. 2010;10(9):621-9. Available from: http://dx.doi.org/10.1016/S1473-3099(10)70139-0.
  8. Mirza IA, Khan FA, Khan KA, Satti L, Ghafoor T, Fayyaz M. Extensively and pre-extensively drug resistant tuberculosis in clinical isolates of multi-drug resistant tuberculosis using classical second line drugs (levofloxacin and amikacin). J Coll Physicians Surg Pak. 2015;25(5):337-41. Available from: http://dx.doi.org/05.2015/JCPSP.337341.
  9. Sterlikov SA, Testov VV. Effektivnost' lecheniya bol'nykh tuberkulyozom s mnozhestvennoy lekarstvennoy ustoychivost'yu vozbuditelya, zaregistrirovannykh v 2010 g [The efficiency of treatment in multidrug-resistant tuberculosis patients registered in 2010]. Tuberkulyoz i bolezni lyogkikh. 2014;3:12-7.
  10. Ramappa V, Guruprasad P. Hepatotoxicity related to antituberculosis drugs: mechanism and management. J Clin Exp Hepatol. 2013;3(1):37-49. Available from: http://dx.doi.org/10.1016/j.jceh.2012.12.001.
  11. Adambekova AD, Adambekov DA, Litvinov VI. Test XPERT MTB/RIF dlya diagnostiki tuberkulyoza i ustoychivosti k rifampitsinu – rezul'taty vnedreniya v Kyrgyzskoy Respublike [XPERT MTB/RIF test for the diagnosis of tuberculosis and rifampicin resistance: results of its introduction in the Kyrgyz Republic]. Tuberkulyoz i bolezni lyogkikh. 2014;1:34-6.
  12. Chan ED, Laurel V, Strand MJ, Chan JF, Huynh M-LN, Goble M, et al. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2004;169(10):1103-9. Available from: http://dx.doi.org/10.1164/rccm.200308-1159OC.
  13. Mitnick C, Bayona J, Palacios E, Shin S, Furin J, Alcantara F, et al. Communitybased therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med. 2003;348(2):119-28. Available from: http://dx.doi.org/10.1056/NEJMoa022928.
  14. Mukherjee JS, Rich ML, Socci AR, Joseph JK, Viru FA, Shin SS, et al. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet. 2004;363(9407):474-81. Available from: http://dx.doi.org/10.1016/S0140-6736(04)15496-2.
  15. Gosling RD, Uiso LO, Sam NE, Bongard E, Kanduma EG, Nyindo M, et al. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med. 2003;168(11):1342-5. Available from: http://dx.doi.org/10.1164/rccm.200305-682OC.
  16. Lange C, Abubakar I, Alffenaar JW, Bothamley G, Caminero JA, Car-valho AC, et al. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J. 2014;44(1):23-63. Available from: http://dx.doi.org/10.1183/09031936.00188313.

Authors informations:

Zhdanova Elena Vasilievna, Phthisiatrician, Department for the Treatment of Multidrug-Resistant Tuberculosis, National Center for Phthisiology

Turdumambetova Gulnura Keneshbekovna, Candidate of Medical Sciences, Associate Professor, Head of the Department of Phthisiology, I.K. Akhunbaev Kyrgyz State Medical Academy

Address for correspondence:

Zhdanova Elena Vasilievna

Phthisiatrician, Department for the Treatment of Multidrug-Resistant Tuberculosis, National Center for Phthisiology

720020, Kyrgyz Republic, Bishkek, Akhunbaev str., 90a

Tel.: (+996) 312 510331

E-mail: zhdanova-ev@mail.ru

Materials on the topic: